AU2119195A - Creation of Inventions and Patents with Artificial Intelligence

AU2119195A – Nipecotic acid derivatives as antithrombic compounds
– Google Patents

AU2119195A – Nipecotic acid derivatives as antithrombic compounds
– Google Patents
Nipecotic acid derivatives as antithrombic compounds

Info

Publication number
AU2119195A

AU2119195A
AU21191/95A
AU2119195A
AU2119195A
AU 2119195 A
AU2119195 A
AU 2119195A
AU 21191/95 A
AU21191/95 A
AU 21191/95A
AU 2119195 A
AU2119195 A
AU 2119195A
AU 2119195 A
AU2119195 A
AU 2119195A
Authority
AU
Australia
Prior art keywords
nip
lys
boc
ala
compound
Prior art date
1994-03-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU21191/95A
Other versions

AU703397B2
(en

Inventor
Patricia Andrade-Gordon
Mary Pat Beavers
William J Hoekstra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ortho Pharmaceutical Corp

Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1994-03-16
Filing date
1995-03-14
Publication date
1995-10-03

1995-03-14
Application filed by Ortho Pharmaceutical Corp
filed
Critical
Ortho Pharmaceutical Corp

1995-10-03
Publication of AU2119195A
publication
Critical
patent/AU2119195A/en

1999-03-25
Application granted
granted
Critical

1999-03-25
Publication of AU703397B2
publication
Critical
patent/AU703397B2/en

2015-03-14
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom

C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members

C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P7/00—Drugs for disorders of the blood or the extracellular fluid

A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P9/00—Drugs for disorders of the cardiovascular system

A61P9/08—Vasodilators for multiple indications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P9/00—Drugs for disorders of the cardiovascular system

A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Nipecotic acid-derived compounds of formula (I): telet-mediated thrombotic disorders.

Description

Nipecoti c acid derivati ves as anti thrombi c compounds Background of the Invention
This is a continuation-in-part of application Serial No. 08/364,896, filed December 27, 1994, which application is a continuation-in-part of application Serial No. 08/213,772, filed March 16, 1994. Platelet aggregation constitutes the initial hemostatic response to curtail bleeding induced by vascular injury. However, pathological extension of this normal hemostatic process can lead to thrombus formation. The final, common pathway in platelet aggregation is the binding of fibrinogen to activated, exposed platelet GPIIb/IIIa. Agents which interrupt binding of fibrinogen to platelet glycoprotein llb/llla (GPIIb/IIIa), therefore, inhibit platelet aggregation. These agents are, therefore, useful in treating platelet-mediated thrombotic disorders such as arterial and venous thrombosis, acute myocardial infarction, unstable angina, reocclusion following thrombolytic therapy and angioplasty, inflammation, and a variety of vaso-occlusive disorders. The fibrinogen receptor (GPIIb/IIIa) is activated by stimuli such as ADP, collagen, and thrombin exposing binding domains to two different peptide regions of fibrinogen: α-chain Arg-Gly-Asp (RGD) and γ-chain His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val (HHLGGAKQAGDV, γ400-411). Since these peptide fragments themselves have been shown to antagonize (inhibit) fibrinogen binding to GPIIb/IIIa, a mimetic of these fragments would also serve as an antagonist. In fact, prior to this invention, potent RGD-based or RGD mimetic antagonists have been revealed which inhibit both fibrinogen binding to GPIIb/IIIa and platelet aggregation. Some of these agents have also shown in vivo efficacy as antithrombotic agents and, in some cases, have been used in conjunction with fibrinolytic therapy (e.g., t-PA or streptokinase) as well.
DISCLOSURE OF THE INVENTION The present invention is directed to compounds represented by the following general formula (I):

wherein X1 , X2, Y, Z, R2 and A are as hereinafter defined. Such compounds, based upon structural features of fibrinogen γ400-411 , are platelet
aggregation inhibitors useful in treating platelet-mediated thrombotic disorders such as arterial and venous thrombosis, acute myocardial infarction, reocclusion following thrombolytic therapy and angioplasty, inflammation and unstable angina and a variety of vaso-occlusive disorders. These compounds are also useful as antithrombotics used in conjunction with fibrinolytic therapy (e.g., t-PA or streptokinase). Pharmaceutical compositions containing such compounds are also part of the present invention.
DETAILED DESCRIPTION OF THE INVENTION More particularly, the present invention is directed to compounds of the following formula (I):

wherein
X1 and X2are the same or different and selected from either of H2 or O.
Preferably, each of X1 and X2 is O.
Y is (CH2)m, CH(NHCOR3)(CH2)m, or CH(NH2)CH2)m.
A is NHR1 , C(NH)NH2 or a cycloalkyl ring containing a nitrogen therein which ring is selected from any of piperidin-2-yl, piperidin-3-yl, piperidin-4-yl,

pyrrolidin-2-yl and pyrrolidin-3-yl. More preferably, the ring is selected from any of piperidin-2-yl, piperidin-3-yl, or piperidin-4-yl.
Z is (CH2)n or CH(CO2R4)(CH2)n. Preferably, Z is (CH2)2.
R1 is H, alkyl, or CH(NH)NH2. More preferably, R1 is H or alkyl. Most preferably, R1 is hydrogen
R2 is H or alkyl. Preferably, R2 is hydrogen.
R3 is alkoxy or alkyl. Preferably, R3 is t-butoxy or methyl. Most preferably, R3 is t-butoxy.
R4 is alkyl or arylalkyl such as benzyl. Preferably, R4 is methyl.
R6 is H, alkyl or arylalkyl such as benzyl. When R6 is other than H, it is in its prodrug form. m is the integer 0, 1 , 2, or 3. n is the integer 0, 1 , or 2.
As used herein, unless otherwise noted alkyl and alkoxy whether used alone or as part of a substituent group, include straight and branched chains having 1-8 carbons. For example, alkyl radicals include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, 3-(2-methyl)butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl and 2-methylpentyl. Alkoxy radicals are oxygen ethers formed from the previously described straight or branched chain alkyl groups. Cycloalkyl groups contain 5-8 ring carbons and preferably 6-7 carbons.
The term “aryl” as used herein alone or in combination with other terms indicates aromatic hydrocarbon groups such as phenyl or naphthyl. The term “arylalkyl” means an alkyl group substituted with an aryl group.
The compounds of the present invention may also be present in the form of a pharmaceutically acceptable salt. The pharmaceutically acceptable salt

generally takes a form in which the nitrogen on the 1 -piperidine substituent is protonated with an inorganic or organic acid. However when X2 is H2 the ring nitrogen may be subject to salt formation. Representative organic or inorganic acids include hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benezenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharic or trifluoroacetic.
Particularly preferred compounds of the present invention include compounds represented by the formula:

R=H m=3 n=2 R5=L-NHBoc R6 is benzyl (Bn) (CP #1);
R=H m=3 n=2 R5=L-NHBoc R6 is H (CP #2);
R=H m=3 n=2 R5=D-NHBoc R6 is H (CP P3);
R=H m=3 n=2 R5=L-NH2 R6 is H (CP #4).
R=H m=3 n=2 R5=H R6 is H (CP #5);
R=H m=3 n=l R5=L-NHAcR6 is H (CP #6);
R=H m=3 n=2 R5=L-NHAc R6 is H (CP #7);
R=C(NH)NH2 m=2 n=2 R5=L-NHBoc R6 is H (CP #8);
R=H m=3 n=3 R5=L-NHBoc R6 is H (CP #9);
R=H m=3 n=2 R5=D-NH2 R6 is H (CP #10);
R=H m=3 n=3 R5=D-NHBoc R6 is H (CP #11);
R=H m=3 n=l R5=D-NHBoc R6 is H (CP #12);
R=H m=3 n=2 R5=D-NHAc R6 is H (CP #13);
3-S-isomer of CP#3 R6 is H (CP #14);
R=i-Pr m=3 n=2 X=L-NHBoc R6 is H (CP #15);
3-R-isomer of CP#3 R6 is H (CP #16);

The compounds of the invention may be prepared from commercially available starting materials by the following reaction schemes AA, AB, AC and AD.
The compounds of the invention where X1 and X2 are each oxygen may be prepared by following scheme AA. In this scheme nipecotic acid (either the racemic mixture or either separate enantiomer) may be treated with a lower alkyl alcohol and a catalytic amount of an acid from about room temperature to reflux, to give the ester derivative AA1 as the acidic salt.
Typical alcohols which include ethanol, methanol, isopropanol and butanol may be paired with acidic catalysts such as p-toluenesulfonic acid, HCl or sulfuric acid. The preferred reagents are methanol and HCl. Derivative AA1 may be acylated at the ring nitrogen with a variety of acylating agents to give derivative AA2. Typical reaction conditions include treating AA1 with the acylating agent and an equivalent of an organic base in an inert solvent at room temperature for 15 min to 2 h. The preferred acylating agents are amino protected amino acids or amino protected aminoalkyl carboxylic acids, which are activated with coupling reagents such as DCC (1 ,3-dicyclohexylcarbodiimide) and BOP-CI (bis(2-oxo-3-oxazolidinyl)phosphinic chloride). However, amino protected acid derivatives such as anhydrides, N- oxysuccinimides, and acid chlorides may also be used. Suitable protecting groups include lower alkyl carbamates, branched alkyl carbamates, benzyl carbamates, acetamides, and substituted acetamides. The choice of acylating agent and its amino protecting group(s) is the factor that determines substituents Y and R1 in the compounds of Formula I where X1 and X2 are O. In Scheme AA, the protected amino acid is the diamino acid of the formula NH(Boc)CHCO2H(CH2)nN(Cbz), which allows for selective deprotection of the two amino groups at a latter point in the scheme. This choice is only meant to illustrate the invention and not to limit it.
Derivative AA2 can be treated with a base and a suitable solvent mixture to give the salt derivative AA3. Suitable inorganic bases include NaOH, KOH, Mg(OH)2, LiOH , Na2CO3 and NaHCO3, which may be combined with mixtures of THF and water at room temperature for 1-6 h to give the desired product. The organic bases which may be used include triethylamine, tributylamine, diisopropylethylamine and tetramethylguanidine. These bases

can be used with organic solvents at room temperature to reflux for 1-6 h to give salt AA3.
The preferred reaction conditions (which are illustrated) are the treatment of AA2 with LiOH, water and THF at room temperature for 1 h.
Other suitable inorganic basis may be used such as NaOH, KOH, Mg(OH)2,
NaCO3 and
NaHCO3. Should another such base be used, the Li in AA3 would, of course, be replaced by the appropriate metal substituent. Derivative AA3 may be treated with a carboxy protected carboxyalkylamine or a carboxy protected amino acid under standard amino acid coupling conditions to give the disubstituted nipecotic derivative AA4. Acceptable coupling conditions include employing peptide coupling agents such as DCC, BOP-CI and EDC (ethyl dimethylaminopropylcarbodiimide● HCl). Suitable carboxy protecting groups include benzyl carbamates, substituted benzyl carbamates, alkyl carbamates and branched alkyl carbamates where the choice of protecting group is obvious to those skilled in chemical synthesis. The illustrated example uses NH2(CH2)nCO2-(Bzl) as the protected amino acid. Once again the choice of amino acid and its carboxy protecting group determine substituents R2 and Z in the compounds of Formula I where X1 and X2 are O. Derivative AA4 may be selectively deprotected in accordance with the the requirements of the amino or carboxy protecting group. In the illustrated example, the protecting groups on the 3-carboxy group and one of the amino groups are simultaneously removed by catalytic hydrogenation using Pd/C in a H2 atmosphere to give derivative AA5.

Scheme AB illustrates the preparation of compounds of Formula I where X2 is O and X1 is H2 Nipecotic acid (either the racemic mixture or either separate enantiomer) may be treated with a alkyl alcohol and a catalytic amount of an acid from about room temperature to reflux, to give the ester derivative AB1 as the acidic salt. Typical alcohols include ethanol, methanol, isopropanol and butanol. The acid catalysts include p-toluenesulfonic acid, HCl and sulfuric acid where the preferred reagents are methanol and HCl. Derivative AB1 may be acylated at the ring nitrogen with a variety of acylating agents to give derivative AB2. Typical reaction conditions include treating AB1 with the acylating agent and an equivalent of an organic base in an inert solvent at room temperature for 15 min to 2 h. The preferred acylating agents are amino protected amino acids or amino protected aminoalkyl carboxylic acids, which are activated with coupling reagents such as DCC (1 ,3-dicyclohexylcarbodiimide) and BOP-CI (bis(2-oxo-3-oxazolidinyl)phosphinic chloride). However, amino protected acid derivatives such as anhydrides, N-oxysuccinimides and acid chlorides may also be used. Suitable protecting groups include lower alkyl carbamates, branched alkyl carbamates, benzyl carbamates, acetamides, and substituted acetamides. The choice of amino acid and its amino protecting group(s) is the factor that determines
substituents Y and R1 in the compounds of Formula I. In Scheme AB, the protected amino acid is the diamino acid of the formula
NH(Boc)CHCO2H(CH2)nN(Boc), this choice is only meant to illustrate the invention and not to limit it. Derivative AB2 can be hydrolyzed with a base and a suitable solvent mixture to give derivative AB3. Suitable inorganic bases include NaOH, KOH, Mg(OH)2, LiOH , Na2CO3 and NaHCO3, which may be combined with mixtures of THF and water at room temperature for 1 -6 h to give the desired product. The organic bases which may be used include triethylamine, tributylamine, diisopropylethylamine and
tetramethylguanidine. These bases can be used with organic solvents at room temperature to reflux for 1-6 h to give AB3. The 3-carboxy group of derivative AB3 may be reduced to give the aldehyde derivative AB4 by using a number of reaction condidtions. Those conditions include the use of lithium1-diisopropylamide with HMPT/THF as a solvent from -78 to 0 °C, N,N-dimethylchloromethyleniminium chloride and lithium t-butoxyaluminum hydride with pyridine as a solvent at -78 °C and standard Rosenmund reduction conditions. The preferred reaction conditions use N,N’-carbonyldiimidazole followed by diisobutylaluminum hydride at -10 °C to give

the aldehyde derivative AB4. AB4 may be treated with a carboxy protected carboxyalkylamine or a carboxy protected amino acid followed by a reducing agent to give the disubstituted nipecotic derivative AB5. Suitable carboxy protecting groups include benzyl carbamates, substituted benzyl carbamates, lower alkyl carbamates and branched alkyl carbamates where the choice of protecting group is obvious to those skilled in chemical synthesis. Reducing agents include sodium cyanoborohydride, lithium cyanoborohydride, sodium-9-cyano-9-hydrido-borabicyclo[3,3,1] nonane, tetrabutylammonium
cyanoborohydride and Pd/C with an acidic solvent where the choice of reducing agent is determined by the protecting groups in use. The illustrated example uses NH2(CH2)nCO2Bzl as the protected amino acid and sodium cyanoborohydride as a reducing agent. This choice of amino acid and its carboxy protecting group determine substituents R2 and Z in the compound and is meant to be illustrative not limiting. Derivative AB5 may be selectively deprotected in accordance with the the requirements of the amino or carboxy protecting group. As illustrated example, the protecting groups on the 3-carboxy group and both amino groups are simultaneously removed by catalytic hydrogenation using Pd/C in a H2 atmosphere to give derivative
AB6.

The compounds of the invention where X1 is oxygen and X2 is H2 and may be prepared by following scheme AC. In this scheme nipecotic acid (either the racemic mixture or the separated enantiomers) may be treated with a lower alkyl alcohol and a catalytic amount of an acid from about room temperature to reflux, to give the ester derivative AC1 as the acidic salt.
Typical alcohols include ethanol, methanol isopropanol and butanol. The acid catalysts include y-toluenesulfonic acid, HCl and sulfuric acid.with methanol and HCl as the reagents of choice. Derivative AC1 may be alkylated at the ring nitrogen with an alkylating agent to give derivative AC2. Alkylating reagents include haloalkylamine synthons such as bromoalkylphthalimides and bromoalkylnitriles, or protected aminoaldehydes via reductive amination procedures ( for conditions, see Scheme AD). Typical reaction conditions include treating AC1 with a base such as sodium hydride or a phase transfer catalyst such as tetrabutylammonium fluoride and an alkylating agent in an inert solvent at room temperature for 15 min to 2 h followed by routine protection of the 3-substituent’s amino group with any of the aforementioned suitable protecting groups. The choice of alkylating agent and its amino protecting group is the factor that determines substituents Y and R1. In Scheme AC the 1- position is substituted with (CH2)NH(Cbz), a choice that is only meant to illustrate the invention and not to limit it. Derivative AC2 can be treated with a base and a suitable solvent mixture to give the salt derivative AC3. As in Scheme AA, Scheme AC shows the use of the preferred LiOH. However, other suitable inorganic bases include NaOH, KOH, Mg(OH)2, Na2CO3 and NaHCO3, which may be combined with mixtures of THF and water at room temperature for 1 -6 h to give the desired product. The organic bases which may be used include triethylamine, tributylamine,
diisopropylethylamine and tetramethylguanidine. These bases can be used with organic solvents at room temperature to reflux for 1-6 h to give salt AC3. The preferred reaction conditions (which are illustrated) are the treatment of AC2 with LiOH, water and THF at room temperature for 1 h. Derivative AC3 may be treated with a carboxy protected carboxyalkylamine or a carboxy protected amino acid under standard amino acid coupling conditions to give the disubstituted nipecotic derivative AC4. Acceptable coupling conditions include employing peptide coupling agents such as DCC, BOP-CI and EDC (ethyl dimethylaminopropyl carbodiimide● HCl). Suitable carboxy protecting groups include benzyl carbamates, substituted benzyl carbamates, alkyl carbamates and branched alkvl carbamates where the choice of orotectinα

group is obvious to those skilled in chemical synthesis. The illustrated example uses NH2(CH2)nCO2Bzl as the protected amino acid. Once again the choice of amino acid and its carboxy protecting group determine substituents R2 and Z in the compounds of Formula I. Derivative AC4 may be selectively deprotected in accordance with the the requirements of the amino or carboxy protecting group. In the illustrated example, the protecting groups on the 3-carboxy group and the 1 -amino group are simultaneously removed by catalytic hydrogenation using Pd/C in a H2 atmosphere to give derivative AC5.

The compounds of the invention where X1 and X2 are each H2 and may be prepared by following scheme AD. In this scheme nipecotic acid (either the racemic mixture or the separated enantiomers) may be treated with a lower alkyl alcohol and a catalytic amount of an acid from about room temperature to reflux, to give the ester derivative AD1 as the acidic salt.
Typical alcohols include ethanol, methanol isopropanol and butanol. The acid catalysts include
β-toluenesulfonic acid, HCl and sulfuric acid. The preferred reagents are methanol and HCl. Derivative AD1 may be alkylated at the ring nitrogen with an alkylating agent to give derivative AD2. Alkylating reagents include haloalkylamine synthons such as bromoalkylphthalimides and
bromoalkylnitriles, or protected aminoaldehydes via reductive amination procedures ( for conditions, see Scheme AD). Typical reaction conditions include treating AD1 with a base such as sodium hydride or a phase transfer catalyst such as tetrabutylammonium fluoride and an alkylating agent in an inert solvent at room temperature for 15 min to 2 h followed by routine protection of the amino group with any of the aforementioned suitable protecting groups. The choice of alkylating agent and its amino protecting group is the factor that determines substituents Y and R1. In Scheme AD the 1 – position is substituted with (CH2)NH(Cbz), a choice that is only meant to illustrate the invention. Derivative AD2 can be hydrolyzed with a base and a suitable solvent mixture to give derivative AD3. Suitable inorganic bases include NaOH, KOH, MgOH, LiOH , Na2CO3 and NaHCO3, which may be combined with mixtures of THF and water at room temperature for 1-6 h to give the desired product. The organic bases which may be used include triethylamine, tributylamine, diisopropylethylamine and tetramethylguanidine. These bases can be used with organic solvents at room temperature to reflux for 1-6 h to give AD3. The 3-carboxy group of derivative AD3 may be reduced to give the aldehyde derivative AD4 by using a number of reaction condidtions. Conditions include the use of lithium diisopropylamide with HMPT/THF as a solvent from -78 to 0 °C, N,N-dimethylchloromethyleniminium chloride and lithium 1-butoxyaluminum hydride with pyridine as a solvent at -78 °C and standard Rosenmund reduction conditions. The preferred reaction conditions use N,N’-carbonyldiimidazole followed by diisobutylaluminum hydride at -10 °C to give the aldehyde derivative AD4.

Derivative AD4 may be treated with a carboxy protected
carboxyalkylamine or a carboxy protected amino acid followed by a reducing agent to give the disubstituted nipecotic derivative AD5. Suitable carboxy protecting groups include benzyl carbamates, substituted benzyl carbamates, lower alkyl carbamates and branched alkyl carbamates where the choice of protecting group is obvious to those skilled in chemical synthesis. Reducing agents include sodium cyanoborohydride, lithium cyanoborohydride, sodium-9-cyano-9-hydrido-borabicyclo[3,3,1] nonane, tetrabutylammonium
cyanoborohydride and Pd/C with an acidic solvent where the choice of reducing agent is determined by the protecting groups in use. The illustrated example uses NH2(CH2)nCO2Bzl as the protected amino acid and sodium cyanoborohydride as a reducing agent. This choice of amino acid and its carboxy protecting group determine substituents R2 and Z in the compound and is meant to be illustrative not limiting. Derivative AD5 may be selectively deprotected in accordance with the requirements of the amino or carboxy protecting group. As illustrated, the protecting groups on the 3-carboxy group and the amino group are simultaneously removed by catalytic hydrogenation using Pd/C in a H2 atmosphere to give derivative AD6.

With regard to starting materials for all schemes, most of the amino acids and the aminoalkylcarboxylic acids needed to produce compounds

where A is NHR1. are commercially available and only require the
manipulation of protecting groups to give the desired compounds of
Formula I. However, to produce the compounds of the invention where A is a cycloalkyl ring containing a nitrogen therein, the 1-substituent (piperidine) must be modified after addition to give desired compounds of Formula I. To produce the compounds where the 1 -substituent is C(O)(CH2)2-4-yl-piperdine, derivatives AA1 or AB1 are acylated with 3-(4-pyridyl)acrylic acid to produce the acylated derivatives AA2 and AB2. using the aforementioned acylation procedures. These derivatives are converted as described in the schemes to give AA4 and AB5. Derivatives AA5 and AB6 may be produced by treating AA4 and AB5 with a suitable reducing agent which in this case removes the protecting group on the carboxy group of the 3-position and reduces the ethylene-substituted pyridine to give the desired compound. The preferred reducing/deprotecting agent is PtO2- The 2 and 3-yl pipeldines may be produced by modifying the acrylic acid derivative by conventional means.
To produce the compounds where the 1-substituent is C(O)(CH2)2-3-yl-pyrrole, derivatives AA1 or AB1 are acylated with 3-(1-benzylpyrrolidin-3-yl)acrylic acid to produce the acylated derivatives AA2 and AB2, using the aforementioned acylation procedures. This substituted pyrrole acrylic acid derivative may be obtained by hydrolyzing the corresponding nitrile derivative with aqueous acid. 3-(1-Benzylpyrrolidin-3-yl)acrylonitrile was synthesized according to the methods described in US Patent 4,002,643, which is incorporated herein by reference. These derivatives are treated as described above (for the six-membered case) to give the compounds of the invention where A is a five-membered ring with a nitrogen contained therein.
To produce diastereomerically-enriched final compounds which contain the Boc-D-Lys and either R- or S-nipecotyl groups (see compounds 14 and 16), the corresponding enantiomerically-enriched nipecotic acid methyl esters were employed at the beginning of the syntheses. Enantiomerically-enriched nipecotic acid methyl esters were isolated by chiral resolution of radamic material as published (A. M. Akkerman, Rec. Trav. Chim. Pays-Bas 1951, 70, 899).
To prepare the pharmaceutical compositions of this invention, one or more compounds of formula (I) or salt thereof of the invention as the active ingredient, is intimately admixed with a pharmaceutical carrier according to

conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intra muscular. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules, caplets, gelcaps and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders,
disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard
techniques. For parenterals, the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described above. The pharmaceutical compositions herein will contain, per unit dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.03 mg to 100 mg/kg (preferred 0.1-30 mg/kg) and may be given at a dosage of from about 0.1-300 mg/kg/day (preferred 1-50 mg/kg/day). The dosages, however, may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.
PHARMACOLOGY
The compounds of the present invention interrupt binding of fibrinogen to platelet glycoprotein IIb/IIIa (GPIIb/IIIa) and thereby inhibit platelet
aggregation. Such compounds are, therefore, useful in treating platelet-mediated thrombotic disorders such as arterial and venous thrombosis, acute myocardial infarction, reocclusion following thrombolytic therapy and angioplasty, and a variety of vaso-occlusive disorders. Because the final,

common pathway in normal platelet aggregation is the binding of fibrinogen to activated, exposed GPIIb/IIIa, inhibition of this binding represents a plausible antithrombotic approach. The receptor is activated by stimuli such as ADP, collagen, and thrombin, exposing binding domains to two different peptide regions of fibrinogen: α-chain Arg-Gly-Asp (RGD) and γ-chain 400-411. As demostrated by the results of the pharmacological studies described hereinafter, the compounds of the present invention have shown the ability to block fibrinogen binding to isolated GPIIb/IIa (ICso’s 3-5800 nM), inhibit platelet aggregation in vitro in the presence of a various of platelet stimuli, and furthermore, have inhibited ex vivo platelet aggregation in animal models.
IN VITRO SOLID PHASE PURIFIED GLYCOPROTEIN IIB/IIIA
BINDING ASSAY.
A 96 well lmmulon-2 microtiter plate (Dynatech-lmmulon) is coated with 50 μl/well of RGD-affinity purified GPIIb/IIIa (effective range 0.5-10 μg/mL) in 10 mM HEPES, 150 mM NaCl, 1 mM at pH 7.4. The plate is covered and incubated overnight at 4°C. The GPIIb/IIa solution is discarded and 150 μl of 5% BSA is added and incubated at RT for 1-3 h. The plate is washed extensively with modified Tyrodes buffer. Biotinylated fibrinogen (25 μl/well) at 2 x final concentration is added to the wells that contain the test
compounds (25 μl/well) at 2 × final concentration. The plate is covered and incubated at RT for 2-4 h. Twenty minutes prior to incubation completion, one drop of Reagent A (Vecta Stain ABC Horse Radish Peroxidase kit, Vector Laboratories, Inc.) and one drop Reagent B are added with mixing to 5 mL modified Tyrodes buffer mix and let stand. The ligand solution is discarded and the plate washed (5 × 200 μl/well) with modified Tyrodes buffer. Vecta Stain HRP-Biotin-Avidin reagent (50 μl/well, as prepared above) is added and incubated at RT for 15 min. The Vecta Stain solution is discarded and the wells washed (5 x 200 μl/well) with modified Tyrodes buffer. Developing buffer (10 mL of 50 mM citrate/phosphate buffer @ pH 5.3, 6 mg o-phenylenediamine, 6 μl 30% H2O2; 50 μl/well) is added and incubated at RT for 3-5 min, and then 2N H2SO4 (50 μl/well) is added. The absorbance is read at 490 nM. The results are shown in Table I.

IN VITRO INHIBITION OF THROMBIN-INDUCED GEL-FILTERED PLATELET AGGREGATION ASSAY.
The percentage of platelet aggregation is calculated as an increase in light transmission of compound treated platelet concentrate vs. control treated platelet concentrate. Blood is obtained from drug free, normal donors into tubes containing 0.13M sodium citrate. Platelet rich plasma (PRP) is collected by centrifugation of whole blood at 200 x g for 10 min at 25°C. The PRP (5 mL) is gel filtered through Sepharose 2B (bed volume 50 mL), and the platelet count is adjusted to 2×107 platelets per sample. The following constituents are added to a siliconized cuvette: concentrated platelet filtrate and Tyrode’s buffer (0.14M NaCl, 0.0027M KCl, 0.012N/ NaHCO3, 0.76 mM Na2HPO4, 0.0055M glucose, 2 mg/mL BSA and 5.0mM HEPES @ pH 7.4) in an amount equal to 350 μl, 50 μl of 20mM calcium and 50 μl of the test compound. Aggregation is monitored in a BIODATA aggregometer for the 3 min following the addition of agonist (thrombin 50 μl of 1 unit/mL). The results are shown in Table I.
EX VIVO DOG STUDY
Adult mongrel dogs (8-13 kg) were anesthetized with sodium pentobarbital (35 mg/kg, i.v.) and artificially respired. Arterial blood pressure and heart rate were measured using a Millar catheter-tip pressure transducer inserted in a femoral artery. Another Millar transducer was placed in the left ventricle (LV) via a carotid artery to measure LV end diastolic pressure and indices of myocardial contractility. A lead II electrocardiogram was recorded from limb electrodes. Catheters were placed in a femoral artery and vein to sample blood and infuse drugs, respectively. Responses were continuously monitored using a Modular Instruments data aquisition system.
Arterial blood samples (5-9 ml) were withdrawn into tubes containing 3.8% sodium citrate to prepare platelet rich plasma (PRP) and to determine effects on coagulation parameters: prothrombin time (PT) and activated partial thromboplastin time (APTT). Separate blood samples (1.5 ml) were withdrawn in EDTA to determine hematocrit and cell counts (platelets, RBC’s and white cells). Template bleeding times were obtained from the buccal surface using a symplate incision devise and Whatman filter paper.

Aggregation of PRP was performed using a BioData aggregometer. Aggregation of whole blood used a Chronolog impedance aggregometer. PT and APTT were determined on either a BioData or ACL 3000+ coagulation analyser. Cells were counted with a Sysmex K-1000.
Compound 17 was solubilized in a small volume of dimethylformamide (DMF) and diluted with saline to a final concentration of 10% DMF. Compound 17 was administered by the intravenous route with a Harvard infusion pump. Doses of 0.3, 1 , 3, and 10 mg/kg were given in a cumulative fashion to each animal. Each dose was administered over a 15 min interval at a constant rate of 0.33 ml/min. Data were obtained after each dose and 30 and 60 min following the end of drug administration.
Compound 17 caused marked inhibition of ex vivo platelet aggregation responses. Thus, in whole blood, Compound 17 inhibited collagen-stimulated aggregation in doses of 0.3-10 mg/kg with marked inhibition of collagen stimulated platelet ATP release at 10 mg/kg. In PRP, Compound 17 also inhibited collagen stimulated platelet aggregaton with marked activity at 0.3 mg/kg. Gamma thrombin induced aggregation of PRP was inhibited at doses of 3.0 mg/kg and above. In both PRP and whole blood, platelet function began to recover within 30 – 60 min, suggesting a relatively short duration of drug action. Compound 17 had no measurable hemodynamic effect in doses up to 10 mg/kg, iv. The drug produced an increase in template bleeding time at 3 and 10 mg/kg with rapid recovery post treatment. No effects on coagulation (PT or APTT) were observed during treatment and platelet, white and RBC counts were unchanged at any dose of Compound 17.
The results indicate that Compound 17 is a broadly effective inhibitor of platelet aggregation ex vivo (antagonizing both collagen and thrombin pathways) following iv adminnstration of doses ranging from 0.3-10 mg/kg. The antiaggregatory effect is relatively short and is accompanied by increases in bleeding time at the higher doses. No other hemodynamic or hematologic effects are observed.

IN VIVO DOG STUDY
Compound 16 was tested in the following in vivo dog model to determine its therapeutic efficacy
Surgical Preparation
Adult mongrel dogs of either sex 9-13 kg) were anesthetized with pentobarbital sodium (35 mg/kg, i.v.) and ventilated with room air via an endotracheal tube (12 strokes/min, 25 ml/kg). For arterial pressure determination, the left carotid artery was cannulated with a saline-filled polyethylene catheter (PE-200) and connected to a Statham pressure transducer (P23ID, Oxnard, CA). Mean arterial diastolic blood pressure. Heart rate was monitored using a cardiotachometer (Biotach, Gould

Electronics, Cleveland, OH) triggered from a lead II electrocardiogram generated by limb leads. A jugular vein was cannulated (PE-200) for drug administration. The left femoral artery and the left femoral vein were cannulated with silicon treated (Sigmacote, Sigma Chemical Co., St. Louis, MO), saline filled polyethylene tubing (PE-200) and connected with a 5 cm section of silicon treated tubing (PE-240) to form an extracorporeal arteriovenous shunt (A-V). Shunt patency was monitored using a Doppler flow system (model VF-1 , Crystal Biotech Inc., Hopkinton, MA) and proximal to the locus of the shunt. All parameters were monitored continuously on a polygraph recorder (Gould TA-4000, Oxnard CA) at a paper speed of 10 mm/min.
Protocol
On completion of a 15 min post surgical stabilization period, an occlusive thrombus was formed by the introduction of a thrombogenic surface (O braided silk thread, 5 cm in length, Ethicon Inc., Somerville, NJ) into the shunt. Four consecutive 15 min shunt periods were employed with the first consisting of a vehicle infusion followed by increasing concentrations of Compound 16, SC-47643, saline with DMF or saline with citric acid
administered as a bolus followed by an infusion beginning 5 min. before insertion of the thrombogenic surface and continued for an additional 15 min. AT the end of each 15 min shunt period the silk was carefully removed and weighed. A fifth shunt immediately following the total cumulative treatment dose was used to assess patency duration as indicated by time to total occlusion. Thrombus weight was calculated by subtracting the weight of the silk prior to placement from the total weight of the silk on removal from the shunt. Arterial blood was withdrawn prior to the first shunt and after each shunt period for determination of whole blood collagen-induced platelet aggregation, thrombin-induced platelet degranulation (platelet ATP release), prothrombin time and platelet count. Template bleeding time was performed beginning 10 min. into each shunt period.
Hematologic Studies Platelet, WBC and RBC counts and hematocrit determinations were performed on whole blood collected in 2 mg/ml disodium EDTA using a Sysmex™ K1000 (Baxter Laboratories, McGraw Park, IL).

Whole blood platelet aggregation and ATP release were measured using a lumi-aggregation and ATP release were measured using a lumi-aggregometer (Chrono-log, Havertown, PA) by recording the change in impedance (platelet aggregation) and light transmission (ATP-release) through a stirred (1000 rpm) suspension of whole blood maintained at 37 C. Blood samples were collected in 0.01 M of sodium citrate and diluted 50% with saline supplemented with 0.5 mM Ca (25 μl of 0.02 M CaCl2 and 20 μl of luciferol (Chrono-log, Havertown, PA). Final volume was 1 ml. Aggregation was induced with collagen (2μg/ml) while in a separate sample, platelet degranulation was monitored using thrombin (0.5 U/ml) (Chrono-log,
Havertown, PA) and the changes in impedance and luminescence recorded over 6 min. Prothrombin time (PT) was monitored using a microsample coagulation analyzer (Ciba Corning 512, Corning, NY). Template bleeding time as performed by making an incision into the gum (Surgicutt, ITC Corp, Edison, NJ) and the time to clot formation monitored.
Drugs
Compound 16;1 + 0.03, 3 + 0.1 and 5 + 0.3 mg/kg, i.v. (bolus) + mg/kg/hr,i.v. (infusion) was solubilized in saline + DMF (5%) and serially diluted to achieve appropriate concentrations expressed as parent
compound.
Statistical Analysis
The results are shown in Tables2-4. All values are expressed as the mean and standard error of the mean. Statistical significance of the change was assessed based on change from baseline suing analysis of variance and Student’s t-test. Differences were considered significant when P < 0.05. EXAMPLES Protected amino acids were purchased from Bachem Bioscience Inc. Use of protected amino N-hydroxysuccinimide esters precludes the use of BOP-CI (see synthesis of compound 14). Enantiomerically-enriched nipecotic acid methyl esters were isolated by chiral resolution of racemic material as published (A. M. Akkerman, Rec. Trav. Chim. Pays-Bas 1951 , 70, 899). All other chemicals were purchased from Aldrich Chemical Company, Inc. High field 1 H NMR spectra were recorded on a Bruker AC-360 spectrometer at 360 MHz, and coupling constants are given in Herz. Melting points were determined on a Mel-Temp II melting point apparatus and are uncorrected. Microanalyses were performed at Robertson Microlit Laboratories, Inc., Madison, New Jersey or The R. W. Johnson Pharmaceutical Research Institute Analytical Department. Final compounds were purified by recrystallization/precipitation from common organic solvents and/or column chromatography using Merck silica gel-60. Purities were assessed on a combination Beckman/Waters HPLC System and a Phenomenex-Ultracarb 5 ODS(30) column (100×4.6 mm) using an aqueous acetonitrile mobile phase (typically 10% MeCN/90% water). In the Examples and throughout this application, the following abbreviations have the meanings recited hereinafter. Ac = Acetyl Bn or Bzl = Benzyl Boc = t-Butoxycarbonyl BOP-CI = Bis(2-oxo-3-oxazolidinyl)phosphinic chloride Cbz = Benzyloxycarbonyl CP = compound DiBAL= Diisobutylaluminum hydride EDC = Ethyl dimethylaminopropylcarbodiim.de EDTA = Ethylenediaminetetraacetic acid HOBT= Hydroxybenzotriazole i-Pr = Isopropyl NMM = N-Methylmorpholine Nip = Nipecotyl (Unless noted otherwise, racemic at 3-position) PTSA = p-Toluenesulfonic acid RT = room temperature TFA = Trifluoroacetic acid Example 1 - Nα-Boc-D-Lys-S-(+)-Nip-β-Ala-OH (CP #14) To a mixture of Nα-Boc-D-Lys(Cbz)-OH (2.9 g, 7.74 mmol) and CH2Cl2 (80 mL) at 5°C was added BOP-CI (1.96 g, 7.7 mmol) and NMM (0.83 mL, 7.7 mmol). This mixture was stirred for 30 min, treated with S-(+)-nipecotic acid methyl ester hydrochloride (1.39 g, 7.7 mmol) and NMM (0.83 mL), stirred for 2 h at 5°C, and diluted with sat'd NH4CI (50 mL). The organic layer was separated from the aqueous layer, dried with MgSO4, and evaporated to a glassy solid. This solid was purified by flash chromatography (4% EtOH/CH2Cl2) to afford Nα-Boc-D-Lys(Cbz)-S-(+)-Nip-OMe as a white foam: 1 H NMR (CDCI3) δ 7.30 (m, 5 H), 5.50 (m, 1 H), 5.09 (s, 2 H), 4.61 (m, 1 H), 3.92 (m, 1 H), 3.66 (s, 3 H), 3.20 (m, 4 H), 2.79 (m, 1 H), 2.51 (m, 1 H), 2.12 (m, 1 H), 1.50-1.80 (m, 10 H), 1.39 (s, 9 H); MS m/e 506 (MH+). To a solution of Nα-Boc-D-Lys(Cbz)-S-(+)-Nip-OMe (3.52 g, 7.0 mmol) in THF (25 mL) at RT was added aqueous lithium hydroxide (0.19 g in 15 mL water) dropwise over a 3 min period. This solution was stirred for 6 h and evaporated to give a white foam. This foam was slurried with CH2Cl2 (80 mL) at RT and treated sequentially with H-β-Ala-OBn●PTSA (2.43 g, 7.0 mmol), HOBT (5 mg), EDC●HCl (1.98 g, 10.4 mmol), and NMM (0.76 mL, 7.0 mmol). This mixture was stirred for 13 h, diluted with sat'd NH4CI (50 mL), and the layers separated. The organic layer was dried with MgSO4 and evaporated to give a white foam. The foam was purified by flash chromatography (3-4% EtOH/CH2Cl2) to give Nα-Boc-D-Lys(Cbz)-S-(+)-Nip-β-Ala-OBn as a white foam: 1 H NMR (CDCI3) δ 7.35 (m, 10 H), 6.29 (m, 1 H), 5.45 (m, 1 H), 5.12 (s, 2 H), 5.05 (s, 2 H), 5.00 (m, 1 H), 4.55 (m, 1 H), 4.32 (m, 1 H), 3.48 (m, 2 H), 3.19 (m, 4 H), 2.53 (m, 3 H), 2.21 (m, 1 H), 1.84 (m, 1 H), 1.48-1.72 (m, 9 H), 1.42 (s, 9 H); MS m/e 653 (MH+). To a solution of Nα-Boc-D-Lys(Cbz)-S-(+)-Nip-β-Ala-OBn (0.80 g, 1.22 mmol) in THF (15 mL) in a Parr bottle under nitrogen atmosphere was added AcOH (5 mL), water (10 mL), and Pd/C (10%, 0.09 g). This mixture was hydrogenated at 50 psi/RT for 21 h, filtered through Celite, and evaporated to ca. 5 mL. This solution was treated with Et2O (60 mL) to give a white ppt which was filtered and lyophilized to afford 14 as colorless flakes: mp 52-60°C; 1H NMR (DMSO-d6) δ 7.85 (m, 1 H), 6.83 (d, J=7, 1 H), 4.34 (d, J=12, 1 H), 4.22 (m, 1 H), 3.60 (m, 2 H), 3.41 (m, 2 H), 2.98 (t, J=11 , 1 H), 2.88 (m, 1 H), 2.69 (m, 2 H), 2.35 (m, 2 H), 2.12 (m, 1 H), 2.03 (m, 1 H), 1.70 (m, 2 H), 1.4-1.6 (m, 8 H), 1.35 and 1.38 (pr. s, 8.5:1 , 9 H), 1.16 (m, 2 H); IR (KBr) 3450-2860, 1709, 1641 cm-1 ; MS m/e 429 (MH+); [α]25D -15.20° (c 0.63, MeOH). Anal, calcd. for C20H36N4O6●C2H4O2 (488.6): C, 54.08; H, 8.25; N, 11.47. Found: C, 54.64; H, 8.26; N, 10.79. Example 2 - Nα-Boc-L-Lys(Cbz)-Nip-β-Ala-OBn (CP #1 ) Compound 1 ,, prepared starting from Nα-Boc-L-Lys(Cbz)-OH and racemic nipecotic acid methyl ester, as in Example 1 , was isolated as a glass: 1 H NMR (CDCl3) δ 7.29 (m, 10 H), 6.51 (m, 1 H), 5.39 (m, 1 H), 5.11 (s, 2 H), 5.06 (s, 2 H), 4.94 (m, 1 H), 4.54 (m, 2 H), 4.18 (m, 1 H), 4.02 (d, J=10, 1 H), 3.61 (m, 1 H), 3.48 (m, 2 H), 3.17 (m, 4 H), 2.54 (m, 3 H), 2.20 (m, 1 H), 1.83 (m, 1 H), 1.67 (m, 2 H), 1.51 (m, 4 H), 1.39 (s, 9 H); MS m/e 653 (MH+); Anal, calcd. for C35H48N4O8●1.5H2O (679.8): C, 61.84; H, 7.56; N, 8.24. Found: C, 62.00; H, 7.25; N, 8.23. Example 3 - Nα-Boc-L-Lys-Nip-β-Ala-OH (CP #2) Compound 2, prepared by hydrogenolysis of 1, as in Example 1 , was isolated as a white foam: 1H NMR (DMSO-d6) δ 8.00 (m, 1 H), 7.86 (m, 1 H), 4.29 (m, 2 H), 3.82 (m, 1 H), 3.11 (m, 3 H), 2.70 (m, 2 H), 2.53 (m, 1 H), 2.31 (m, 2 H), 2.17 (m, 2 H), 1.4-1.9 (m, 10 H), 1.34 and 1.36 (pr. s, 1 :1 , 9 H), 1.23 (m, 2 H); MS m/e 429 (MH+); [α]25 D +o.85° (c 0.82, MeOH). Anal, calcd. for C20H36N4O6●1.5H2O (518.6): C, 53.27; H, 8.16; N, 10.80. Found: C, 53.61 ; H, 8.18; N, 10.47. Example 4 - Nα-Boc-D-Lys-Nip-β-Ala-OH (CP #3) Nα-Boc-D-Lys(Cbz)-Nip-β-Ala-OBn, prepared starting from racemic nipecotic acid methyl ester and Nα-Bpc-D-Lys(Cbz)-OH, as in Example 1 , was isolated as a white foam: 1H NMR (CDCl3) δ 7.32 (m, 10 H), 6.59 (m, 1 H), 5.45 (m, 1 H), 5.12 (s, 2 H), 5.07 (s, 2 H), 4.94 (m, 1 H), 4.56 (m, 1 H), 4.12 (m, 1 H), 3.51 (m, 2 H), 3.17 (m, 3 H), 2.57 (m, 2 H), 2.21 (m, 1 H), 1.89 (m, 1 H), 1.45-1.79 (m, 11 H), 1.41 (s, 9 H); MS m/e 653 (MH+). Compound 3, prepared by hydrogenolysis of Nα-Boc-D-Lys(Cbz)-Nip-β-Ala-OBn, as in Example 1 , was isolated as colorless flakes: mp 48-54°C; 1 H NMR (DMSO-d6) δ 7.96 (m, 1 H), 6.82 (m, 1 H), 4.30 (m, 2 H), 3.81 (m, 1 H), 3.12 (m, 4 H), 2.69 (m, 2 H), 2.56 (m, 1 H), 2.33 (m, 2 H), 2.14 (m, 2 H), 1.80 (m, 2 H), 1.4-1.7 (m, 9 H), 1.32 and 1.34 (pr. s, 1 :1 , 9 H), 1.22 (m, 2 H); IR (KBr) 3580-2770, 1711 , 1642 cm-1 ; MS m/e 429 (MH+); [α]25 D -7.78° (c 1.71 , MeOH). Anal, calcd. for C20H36N4O6●2C2H4O2●0.5H2O (557.6): C, 51.69; H, 8.13; N, 10.05. Found: C, 51.46; H, 8.11 ; N, 10.10. Example 5 - Nα-Boc-D-Lys-Nip-L-Asp-OMe (CP #18). Nα-Boc-D-Lys(Cbz)-Nip-L-Asp(OBn)-OMe, prepared from H-L-Asp(OBn)-OMe and Nα-Boc-D-Lys(Cbz)-Nip-OH, as in Example 1 , was isolated as a glass: 1 H NMR (CDCl3) δ 7.36 (m, 10 H), 6.84 (m, 1 H), 5.40 (m, 1 H), 5.14 (s, 2 H), 5.09 (s, 2 H), 4.88 (m, 2 H), 4.54 (m, 1 H), 4.30 (m, 1 H), 3.68 (s, 3 H) 3.19 (m, 3 H) 3.03 (m, 1 H), 2.89 (m, 1 H), 2.29 (m, 1 H), 1.43-2.06 (m, 12 H), 1.40 (s, 9 H); MS m/e 711 (MH+). Compound 18, prepared by hydrogenolysis of Nα-Boc-D-Lys(Cbz)-Nip-L-Asp(OBn)-OMe, as in Example 1 , was isolated as white foam:1H NMR (DMSO-d6) δ 8.33 (m, 1 H), 6.77 (d, J=7, 1 H), 4.32 (m, 3 H), 3.82 (m, 1 H), 3.59 (s, 3 H), 2.96 (m, 2 H), 2.73 (m, 3 H), 2.46 (m, 2 H), 2.34 (m, 1 H), 1.79 (m, 3 H), 1.4-1.7 (m, 8 H), 1.34 and 1.37 (pr. s, 1 :1 , 9 H), 1.27 (m, 2 H); MS m/e 487 (MH+); [α]25 D -3.57° (c 0.56, MeOH). Anal, calcd. for C22H38N4O8●C2H4O2●H2O (564.6): C, 51.05; H, 7.85; N, 9.92. Found: C, 50.89; H, 7.88; N, 9.74. Example 6 - H-L-Lys-Nip-β-Ala-OH (CP #4) To a solution of compound 2 (0.30 g, 0.70 mmol) in MeOH (10 mL) and water (10 mL) at RT was added HCl (0.50 mL, cone). This solution was stirred for 1 h and evaporated to ca. 2 mL oil. This oil was treated with MeCN (20 mL), filtered, washed with Et2O (3×20 mL), and dried to afford 4 as a white powder: mp 65-75°C; 1 H NMR (DMSO-d6) δ 8.23 (m, 3 H), 8.06 (m, 3 H), 4.33 (m, 2 H), 3.73 (m, 4 H), 3.25 (m, 2 H), 3.01 (m, 1 H), 2.72 (m, 2 H), 2.44 (m, 1 H), 2.34 (m, 2 H), 1.5-1.8 (m, 6 H), 1.35 (m, 4 H); MS m/e 329 (MH+); Anal, calcd. for C15H28N4O4●2HCl●2H2O (437.4): C, 41.19; H, 7.84; N, 12.81. Found: C, 40.97; H, 7.75; N, 12.44. Example 7 - N-(Nε-Aminocaproyl)-Nip-β-Ala-OH (CP #5) N-(Nε-Boc-aminocaproyl)-Nip-β-Ala-OBn, prepared starting from racemic nipecotic acid methyl ester and Nε-Boc-aminocaproic acid N-oxysuccinimide ester, as in Example 1 , was isolated as an oily solid: 1 H NMR (CDCl3) δ 7.34 (m, 5 H), 6.51 (m, 1 H), 5.12 (s, 2 H), 4.60 (m, 1 H), 4.39 (m, 1 H), 3.90 (m, 1 H), 3.71 (t, 1 H), 3.52 (m, 3 H), 3.19 (m, 4 H), 2.59 (m, 2 H), 2.30 (m, 2 H), 1.85 (m, 3 H), 1.63 (m, 2 H), 1.51 (m, 2 H), 1.42 (s, 9 H), 1.34 (m, 2 H); MS m/e 504 (MH+). Compound 5, prepared by hydrogenolysis and then acid hydrolysis of N-(Nε-Boc-aminocaproyl)-Nip-β-Ala-OBn, as in Example 1 , was isolated as a glass: 1 H NMR (DMSO-d6) δ 8.18 (t, J=5, 1 H), 8.04 (br. s, 3 H), 4.28 (m, 2 H), 3.78 (m, 2 H), 3.20 (m, 3 H), 2.99 (t, J=12, 1 H), 2.71 (d, J=6, 2 H), 2.39 (m, 2 H), 2.31 (m, 2 H), 2.16 (m, 1 H), 1.79 (m, 1 H), 1.61 (m, 4 H), 1.42 (t, J=6, 2 H), 1.28 (m, 2 H), 1.19 (m, 1 H); MS m/e 314 (MH+); Anal, calcd. for C1 5H27N3O4●2HCl (386.3): C, 46.04; H, 7.57; N, 10.88. Found: C, 45.91 ; H, 7.63; N, 11.17. Example 8 - N-[3-(4-Piperidinepropionyl)]-Nip-β-Ala-OH (CP #17) N-[3-(4-Pyridineacryloyl)]-Nip-β-Ala-OBn, prepared starting from 3-(4-pyridine)acrylic acid and racemic nipecotic acid methyl ester, as in Example 1 , was isolated as a glass: 1 H NMR (CDCl3) δ 8.61 (d, J= 4 Hz, 2 H), 7.52 (d, J= 15 Hz, 1 H), 7.35 (m, 7 H) 7.03 (d, J= 15 Hz, 1 H), 6.58 (m, 1 H), 5.12 (s, 2 H), 4.40 (m, 1 H), 3.89 (m, 1 H), 3.51 (m, 2 H), 3.38 (m, 2 H), 2.60 (t, J= 6 Hz, 2 H), 2.31 (m, 1 H), 1.97 (m, 2 H), 1.74 (m, 1 H), 1.56 (m, 1 H); MS m/e 422 (MH+). To a solution of N-[3-(4-Pyridineacryloyl)]-Nip-β-Ala-OBn (0.56 g, 1.33 mmol) in EtOH (20 mL) and water (10 mL) under nitrogen atmosphere was added HCl (0.66 mL, 4.0 M in dioxane) and platinumIV oxide (0.060 g). This mixture was hydrogenated at 50 psi/RT for 22 h, filtered through Celite, and evaporated to ca. 5 mL. This solution was treated with MeCN (30 mL). filtered, washed with Et2O (3×20 mL), and dried to give 17 as a pale yellow foam: 1H NMR (DMSO-d6) δ 9.02 (br. s, 2 H), 8.03 (m, 1 H), 7.46 (m, 1 H), 4.28 (t, J=7, 1 H), 4.11 (m, 1 H), 3.79 (m, 1 H), 3.44 (t, J=7, 1 H), 3.19 (m, 3 H), 3.06 (t, J=12, 1 H), 2.75 (d, J=11 , 1 H), 2.53 (m, 1 H), 2.32 (m, 4 H), 2.12 (m, 1 H), 1.77 (m, 2 H), 1.4-1.7 (m, 7 H), 1.27 (m, 2 H), 1.18 (t, J=6, 1 H); MS m/e 340 (MH+); Anal, calcd. for C1 7H29N3O4●2HCl (412.4): C, 49.52; H, 7.58; N, 10.19. Found: C, 49.15; H, 7.02; N, 10.48. Accurate protonated mass calcd. for C17H29N3O4: 340.2236 amu. Found: 340.2245 amu. Example 9 - Nα-Ac-L-Lys-Nip-Gly-OH (CP #6) Nα-Ac-L-Lys(Boc)-Nip-Gly-OBn , prepared starting from Nα-Ac-L-Lys(Boc)-OH and racemic nipecotic acid methyl ester (see 14), was isolated as a glass: 1 H NMR (CDCl3) δ 7.35 (m, 5 H), 6.97 (m, 1 H), 6.38 (m, 1 H), 5.14 (s, 2 H), 4.70 (m, 1 H), 4.46 (m, 1 H), 4.06 (dd, J= 5, 16 Hz, 2 H), 3.71 (m, 1 H), 3.10 (m, 2 H), 1.99 (s, 3 H), 1.91 (m, 2 H), 1.64 (m, 1 H), 1.41 -1.60 (m, 1 H), 1.39 (s, 9 H); MS m/e 547 (MH+). Compound 6, prepared by hydrogenolysis of Nα-Ac-L-Lys(Boc)-Nip-Gly-OBn, as in Example 1 , and then TFA-mediated Boc removal (for method, see M. Bodanszky The Practice of Peptide Synthesis, Springer-Verlag: New York, 1984), was isolated as a tan powder: mp 40-55°C; 1 H NMR (DMSO-d6) δ 8.24 (t, J=6, 1 H), 8.03 (d, J=8, 1 H), 7.75 (br. s, 3 H), 4.24 (m, 1 H), 3.72 (t, J=6, 2 H), 3.61 (m, 2 H), 2.72 (m, 2 H), 1.83 (s, 3 H), 1.78 (m, 2 H), 1.63 (m, 2 H), 1.4-1.6 (m, 8 H), 1.28 (m, 4 H); MS m/e 357 (MH+); Anal, calcd. for C16H28N4O5●3C2HF3O2 (698.5): C, 37.83; H, 4.47; N, 8.02. Found: C, 37.91 ; H, 4.89; N, 8.47. Example 10 - Nα-Ac-L-Lys-Nip-β-Ala-OH (CP #7) Nα-Ac-L-Lys(Boc)-Nip-β-Ala-OBn , prepared starting from Nα-Ac-L-Lys(Boc)-OH and racemic nipecotic acid methyl ester as, in Example 1 , was isolated as a white foam: 1 H NMR (CDCl3) δ 7.34 (m, 5 H), 6.53 (m, 2 H), 5.12 (s, 2 H), 4.58 (m, 1 H), 4.10 (m, 1 H), 3.72 (m, 1 H), 3.54 (m, 2 H), 3.11 (m, 3 H), 2.59 (m, 2 H), 2.24 (m, 1 H), 2.01 (s, 3 H), 1.88 (m, 1 H), 1.73 (m, 2 H), 1.52 (m, 8 H), 1.40 (s, 9 H), 1.31 (m, 1 H); MS m/e 561 (MH+). Compound 7, prepared by hydrogenolysis of Nα-Ac-L-Lys(Boc)-Nip-β-Ala-OBn, as in Example 1 , and then acid hydrolysis, as in Example 6, was isolated as a white foam: mp 53-67°C; 1H NMR (DMSO-d6) δ 8.13 (m, 1 H), 8.00 (m, 1 H), 7.91 (d, J=15, 3 H), 4.64 (m, 1 H), 4.36 (m, 1 H), 3.87 (m, 1 H), 3.66 (m, 2 H), 3.23 (m, 3 H), 2.99 (m, 1 H), 2.68 (m, 2 H), 2.59 (m, 1 H), 2.38 (m, 2 H), 2.11 (m, 1 H), 1.80 (s, 3 H), 1.63 (m, 1 H), 1.4-1.6 (m, 5 H), 1.24 (m, 3 H); MS m/e 371 (MH+); Anal, calcd. for C17H30N4O5●2HCl●2H2O (479.4): C, 42.59; H, 7.57; N, 11.69. Found: C, 43.83; H, 7.79; N, 10.91. Example 11 - Nα-Boc-L-Arg-Nip-β-Ala-OH (CP #8) Nα-Boc-L-Arg(Cbz)-Nip-β-Ala-OBn, prepared starting from Nα-Boc-L-Arg(Cbz2)-OSu and racemic nipecotic acid methyl ester, as in Example 1 , was isolated as a glass: 1H NMR (CDCl3) δ 7.33 (m, 10 H), 6.69 (m, 1 H), 5.70 (m, 1 H), 5.13 (s, 2 H), 5.03 (s, 2 H), 4.59 (m, 1 H), 4.29 (m, 1 H), 3.52 (m, 2 H), 3.28 (m, 1 H), 3.09 (m, 3 H), 2.60 (m, 3 H), 2.18 (m, 1 H), 1.49-1.90 (m, 11 H), 1.42 (s, 9 H); MS m/e 681 (MH+). Compound 8, prepared by hydrogenolysis of Nα-Boc-L-Arg(Cbz)-Nip-β-Ala-OBn, as in Example 1 , was isolated as a white foam: mp 47-55°C; 1H NMR (DMSO-d6) δ 9.53 (m, 1 H), 7.85 (m, 2 H), 6.96 (m, 1 H), 4.32 (m, 2 H), 3.84 (m, 1 H), 3.38 (m, 2 H), 3.03 (m, 4 H), 2.20 (m, 3 H), 1.74 (m, 2 H), 1.4-1.7 (m, 8 H), 1.35 (s, 9 H), 1.24 (m, 2 H); MS m/e 457 (MH+); Anal, calcd. for C20H36N6O6●1.5C2H4O2 (546.6): C, 50.54; H, 7.74; N, 15.37. Found: C, 50.24; H, 7.96; N, 15.26. Example 12 - Nα-Boc-L-Lys-Nip-γ-aminobutyric acid (CP #9) Nα-Boc-L-Lys(Cbz)-Nip-γ-aminobutyric acid benzyl ester, prepared starting from Nα-Boc-L-Lys(Cbz)-OH and racemic nipecotic acid methyl ester (see I-1 , I-2), was isolated as a glass: 1 H NMR (CDCl3) δ 7.33 (m, 10 H), 6.48 (m, 1 H), 6.16 (m, 1 H), 5.40 (m, 1 H), 5.11 (s, 2 H), 5.08 (s, 2 H), 4.89 (m, 1 H), 4.58 (m, 1 H), 4.07 (m, 1 H), 3.22 (m, 5 H), 2.52 (m, 1 H), 2.40 (m, 2 H), 1.50-2.30 (m, 12 H), 1.42 (s, 9 H), 1.33 (m, 1 H); MS m/e 667 (MH+). Compound 9, prepared by hydrogenolysis of Nα-Boc-L-Lys(Cbz)-Nip-γ-aminobutyric acid benzyl ester, as in Example 1 , was isolated as a white foam: mp 65-71 °C; 1 H NMR (DMSO-d6) δ 8.25 (m, 1 H), 6.87 (m, 1 H), 4.31 (m, 3 H), 3.74 (m, 2 H), 3.15 (m, 2 H), 2.98 (m, 3 H), 2.69 (m, 2 H), 2.10 (m, 3 H), 1.76 (m, 3 H), 1.4-1.7 (m, 9 H), 1.31 (s, 9 H), 1.21 (m, 2 H); MS m/e 443 (MH+); Anal, calcd. for C21 H38N4O6●2C2H4O2 (562.7): C, 53.37; H, 8.24; N, 9.96. Found: C, 53.94; H, 8.17; N, 9.70. Example 13 - H-D-Lys-Nip-β-Ala-OH (CP #10) Compound 10, prepared by acid hydrolysis of 3, as in Example 6, was isolated as a cream powder: mp 108-128°C; 1 H NMR (DMSO-d6) δ 8.28 (m, 3 H), 8.05 (m, 3 H), 4.31 (m, 2 H), 3.84 (m, 2 H), 3.25 (m, 2 H), 3.09 (m, 2 H), 2.72 (m, 3 H), 2.37 (m, 3 H), 1.80 (m, 1 H), 1.5-1.7 (m, 6 H), 1.33 (m, 4 H); MS m/e 329(MH+); Anal, calcd. for C15H28N4O4●2HCl●C2H4O2 (461.4): C, 44.26; H, 7.43; N, 12.14. Found: C, 43.98; H, 7.27; N, 12.29. Example 14 - Nα-Boc-D-Lys-Nip-γ-aminobutyric acid (CP #11 ) Nα-Boc-D-Lys(Cbz)-Nip-γ-aminobutyric acid benzyl ester, prepared starting from Nα-Boc-D-Lys(Cbz)-OH and racemic nipecotic acid methyl ester, as in Example 1 , was isolated as a glass: 1H NMR (CDCl3) δ 7.31 (m, 10 H), 6.51 (m,1 H), 6.15 (m, 1 H), 5.48 (m, 1 H), 5.10 (s, 1 H), 5.06 (s, 2 H), 4.90 (m, 1 H), 4.55 (m, 1 H), 4.10 (m, 1 H), 3.59 (m, 1 H), 3.23 (m, 5 H), 2.39 (m, 2 H), 2.23 (m, 1 H), 1.84 (m, 2 H), 1.45-1.80 (m, 10 H), 1.38 (s, 9 H), 1.32 (m, 1 H); MS m/e 667 (MH+). Compound 11, prepared by hydrogenolysis of Nα-Boc-D-Lys(Cbz)-Nip-γ-aminobutyric acid benzyl ester, as in Example 1 , was isolated as a tan powder: mp 50-57°C; 1 H NMR (DMSO-d6) δ 7.97 (m, 1 H), 6.91 (m, 1 H), 4.32 (m, 1 H), 4.22 (m, 1 H), 3.82 (m, 1 H), 3.02 (m, 3 H), 2.71 (m, 2 H), 2.52 (m, 1 H), 2.29 (m, 1 H), 2.17 (m, 2 H), 1.84 (m, 5 H), 1.4-1.7 (m, 9 H), 1.33 (s, 9 H), 1.19 (m, 2 H); MS m/e 443 (MH+); Anal, calcd. for C21 H38N4O6●C2H4O2●0.5H2O (571.7): C, 52.53; H, 8.29; N, 9.80. Found: C, 52.91 ; H, 8.21 ; N, 9.39. Example 15 - Nα-Boc-D-Lys-Nip-Gly-OH (CP #12) Nα-Boc-D-Lys(Cbz)-Nip-Gly-OBn, prepared starting from Nα-Boc-D-Lys(Cbz)-OH and racemic nipecotic acid methyl ester, as in Example 1 , was isolated as a glass: 1H NMR (CDCl3) δ 7.39 (m, 10 H), 6.87 (m, 1 H), 5.42 (m, 1 H), 5.19 (s, 2 H), 5.13 (s, 2 H), 4.93 (m, 1 H), 4.60 (m, 1 H), 4.20 (m, 1 H), 4.09 (m, 1 H), 3.40-4.00 (m, 3 H), 3.21 (m, 2 H), 2.61 (m, 1 H), 2.43 (m, 1 H), 1.45-2.20 (m, 10 H), 1.39 (s, 9 H); MS m/e 639 (MH+). Compound 12, prepared by hydrogenolysis of Nα-Boc-D-Lys(Cbz)-Nip-Gly-OBn, as in Example 1 , was isolated as white flakes: mp 66-80°C; 1 H NMR (DMSO-d6) δ 7.82 (m, 1 H), 6.81 (d, J=7, 1 H), 4.34 (m, 2 H), 4.09 (m, 1 H), 3.77 (m, 1 H), 3.48 (m, 1 H), 3.16 (m, 2 H), 2.70 (m, 3 H), 2.44 (m, 2 H), 2.28 (m, 1 H), 1.78 (m, 2 H), 1.4-1.7 (m, 8 H), 1.32 and 1.35 (pr. s, 1 :1 , 9 H), 1.23 (m, 2 H); MS m/e 415 (MH+); Anal, calcd. for C1 9H34N4O6●2C2H4O2 (534.6): C, 51.67; H, 7.92; N, 10.48. Found: C, 52.06; H, 8.33; N, 10.19. Example 16 - Nα-Ac-D-Lys-Nip-β-Ala-OH (CP #13) Nα-Ac-D-Lys(Cbz)-Nip-β-Ala-OBn , prepared starting from Nα-Ac-D- Lys(Cbz)-OH and racemic nipecotic acid methyl ester, as in Example 1 , was isolated as a glass: 1 H NMR (CDCl3) δ 7.32 (m,10 H), 6.54 (m, 1 H), 6.36 (m, 1 H), 5.10 (s, 2 H), 5.02 (s, 2 H), 4.89 (m, 2 H), 4.48 (m, 1 H), 4.04 (m, 1 H), 3.69 (m, 1 H), 3.52 (m, 2 H), 3.17 (m, 3 H), 2.57 (m, 2 H), 2.20 (m, 1 H), 1.98 (s, 3 H), 1.25-1.90 (m, 10 H); MS m/e 595 (MH+). Compound 13, prepared by hydrogenolysis of Nα-Ac-D-Lys(Cbz)-Nip-β-Ala-OBn, as in Example 1 , was isolated as a glass: mp 46-59°C; 1 H NMR (DMSO-d6) 58.11 (m, 3 H), 4.70 (m, 1 H), 4.33 (m, 1 H), 3.74 (m, 1 H), 3.38 (m, 1 H), 3.19 (m, 4 H), 3.00 (m, 1 H), 2.68 (m, 2 H), 2.21 (m, 4 H), 1.82 (s, 3 H), 1.76 (m, 2 H), 1.4-1.7 (m, 7 H), 1.24 (m, 2 H); MS m/e 371 (MH+); Anal, calcd. for C17H30N4O5●2.5C2H4O2 (520.6): C, 50.76; H, 7.74; N, 10.76. Found: C, 51.12; H, 8.04; N, 10.75. Example 17 - Nα-Boc-L-Lys(i-Pr)-Nip-β-Ala-OH (CP #15) Nα-Boc-L-Lys(i-Pr)(Cbz)-Nip-β-Ala-OBn , prepared starting from Nα-Boc-L-Lys(i-Pr)(Cbz)-OH and racemic nipecotic acid methyl ester, as in Example 1 , was isolated as a glass: 1 H NMR (CDCl3) δ 7.33 (m, 10 H), 6.58 (m, 1 H), 5.10 (s, 2 H), 5.08 (s, 2 H), 4.55 (m, 1 H), 4.21 (m, 1 H), 3.73 (m, 1 H), 3.50 (m, 2 H), 3.17 (m, 3 H), 2.55 (m, 2 H), 2.18 (m, 1 H), 1.50-2.00 (m, 13 H), 1.40 (s, 9 H), 1.13 (d, J= 8 Hz, 6 H); MS m/e 695 (MH+). Compound 15, prepared by hydrogenolysis of Nα-Boc-L-Lys(i-Pr)(Cbz)-Nip-β-Ala-OBn, as in Example 1 , was isolated as white flakes: mp 90-123°C; 1H NMR (DMSO-d6) δ 7.93 (m, 1 H), 6.81 (d, J=7, 1 H), 4.36 (m, 1 H), 4.24 (m, 1 H), 3.60 (m, 1 H), 3.37 (m, 1 H), 3.10 (m, 1 H), 2.91 (m, 3 H), 2.62 (m, 3 H), 2.39 (m, 2 H), 2.14 (m, 1 H), 2.05 (m, 1 H), 1.4-1.8 (m, 9 H), 1.34 and 1.37 (pr. s, 1 :1 , 9 H), 1.26 (m, 3 H), 1.13 (d, J=5, 6 H); IR (KBr) 3500-2830, 1704, 1638 cm-1 ; MS m/e 471 (MH+); Anal, calcd. for C23H42N4O6●2C2H4O2 (590.7): C, 54.90; H, 8.53; N, 9.48. Found: C, 54.67; H, 8.65; N, 9.79. Example 18 - Nα-Boc-D-Lys-R-(-)-Nip-R-Ala-OH (CP #16) Compound 16, prepared starting from Nα-Boc-D-Lys(Cbz)-OH and R-(-)-nipecotic acid methyl ester, as in Example 1 , was isolated as a colorless flakes: mp 42-51°C; 1 H NMR (DMSO-d6) δ 7.95 (m, 1 H), 6.82 (d, J=7, 1 H), 4.33 (m, 1 H), 4.19 (m, 1 H), 3.79 (m, 1 H), 3.25 (m, 1 H), 3.04 (t, J=10, 2 H), 2.69 (m, 2 H), 2.34 (m, 1 H), 2.21 (m, 1 H), 2.14 (m, 2 H), 1.78 (m, 2 H), 1.71 (m, 2 H), 1.4-1.6 (m, 9 H), 1.34 and 1.38 (pr. s, 1 :8, 9 H), 1.20 (m, 2 H); MS m/e 429 (MH+). Anal, calcd. for C20H36N4O4●2.5 C2H4O2 (578.7): C, 51.89; H, 8.01 ; N, 9.68. Found: C, 52.05; H, 7.98; N, 9.58. Example 19 - N-(Nε-Aminocaproyl)-3-piperidinemethylaminopropionic acid (CP #19) To a solution of N-(Nε-Boc-aminocaproyl)-nipecotic acid (3.1 g, 9.0 mmol) and THF (50 mL) was added 1 ,1-carbonyldiimidazole (1.45 g, 9.0 mmol). This solution was stirred for 1 h, cooled to -10°C, treated with DiBAL (36.0 mL, 1.0 M in toluene) dropwise over a 20 min period, and stirred for an additional 2 h. This solution was treated with aqueous citric acid (5.0 g in 40 mL water), diluted with CHCl3 (200 mL), and the resultant layers were separated. The aqueous layer was extracted with CHCl3 (100 mL), and the combined organic layers were dried, evaporated, and purified by flash chromatography (4% EtOH/CH2Cl2) to afford N-(Nε-Boc-aminocaproyl)piperidine-3-carboxaldehyde as a glass: 1H NMR (CDCl3) δ 9.65 (d, J= 8 Hz, 1 H), 4.58 (m, 1 H), 4.10 (m, 1 H), 3.65 (m, 1 H), 3.45 (m, 1 H), 3.22 (m, 1 H), 3.14 (m, 2 H), 2.46 (m, 2 H), 2.33 (t, J= 7 Hz, 1 H), 2.09 (m, 1 H), 1.5-1.8 (m, 7 H), 1.39 (s, 9 H), 1.33 (m, 2 H); MS m/e 327 (MH+). To a solution of N-(Nε-Boc-aminocaproyl)piperidine-3-carboxaldehyde (0.69 g, 2.12 mmol) in MeOH (10 mL) at RT was added H-β-Ala-OBn-PTSA (0.74 g, 2.12 mmol) and NaCNBH3 (0.13 g, 2.12 mmol). This mixture was stirred for 2.5 h and evaporated to a white solid. This solid was partitioned between sat'd NaHCO3 (10 mL) and CH2Cl2 (50 mL), and the layers were separated. The aqueous layer was extracted with CH2Cl2 (2×50 mL), and the combined organic layers were dried, evaporated, and purified by flash chromatography (0.5% NH4OH/4-10% EtOH/CH2Cl2) to give N-(Nε-Boc-aminocaproyl)-3-piperidinemethylaminopropionic acid benzyl ester as a glass: 1 H NMR (CDCl3 ) δ 7.33 (m, 5 H), 5.13 (s, 2 H), 4.61 (m, 1 H), 4.28 (m, 1 H), 3.70 (m, 1 H), 3.11 (m, 3 H), 2.85 (m, 3 H), 2.53 (m, 4 H), 2.31 (t, J= 7 Hz, 2 H), 1.5-1.9 (m, 8 H), 1.42 (s, 9 H), 1.29 (m, 3 H), 0.89 (m, 1 H); MS m/e 490 (MH+). To a solution of N-(Nε-Boc-aminocaproyl)-3-piperidinemethylaminopropionic acid benzyl ester (0.28 g, 0.57 mmol) and THF (10 mL) at RT was added aqueous HCl (3.4 mL, 1.0 N). This mixture was stirred for 22 h, evaporated to a glassy solid, triturated with Et2O (3×25 mL), and dried to give a white powder. This powder was dissolved in THF (5 mL) and water (10 mL), transferred t a Parr bottle under nitrogen atmosphere, and treated with Pd/C (0.04 g, 10%). This mixture was hydrogenated at 50 psi/RT for 20 h, filtered through Celite, and evaporated to ca. 5 mL. This solution was treated with MeCN (25 mL), filtered, washed with Et2O (2×25 mL), and dried to give 19 as a colorless glass (HPLC purity> 95%): mp 65-74°C; 1 H NMR (DMSO-d6) δ 9.31 (m, 2 H), 8.12 (br. s, 3 H), 4.18 (m, 2 H), 3.70 (m, 1 H), 3.04 (m, 2 H), 2.67 (m, 5 H), 2.51 (m, 1 H), 2.35 (m, 3 H), 1.87 (m, 2 H), 1.58 (m, 4 H), 1.42 (m, 2 H), 1.30 (m, 4 H); MS m/e 300 (MH+). Accurate protonated mass calcd. for C 15H29N3O3●2HCl (372.3): 300.2287 amu. Found: 300.2306 amu.

Claims (8)

WE CLAIM:

1. A compound represented by the general formula (I):
wherein X1 and X2are the same or different and selected from either of H2 or O; wherein Y is selected from any of (CH2)m. CH(NHCOR3)(CH2)m or
CH((NH2)CH2)m; wherein A is selected from any of NHR 1 , C(:NH)NH2 or a cycloalkyl ring containing a nitrogen therein which ring is selected from any of piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, pyrrolidin-2-yl and pyrrolidin- 3-yl; wherein Z is selected from any of (CH2)n or CH(CO2R4)(CH2)n; wherein R1 is selected from any of H, alkyl, or CH(NH)NH2; wherein R2 is selected from any of H or alkyl; wherein R3 is selected from any of alkoxy or alkyl; wherein R4 is alkyl or arylalkyl; wherein R6 is H, alkyl or arylalkyl; wherein m is the integer 0, 1 , 2, or 3; wherein n is the integer 0, 1 , or 2; or the enantiomer or the pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein Z is (CH2)2.

3. The compound of claim 1 , wherein R1 is H.

4. The compound of claim 1 , wherein R2 is H.

5. The compound of claim 1 , whererin R3 is t-butoxy.

6. The compound of claim 1 , wherein R4 is methyl.

7. The compound of claim 1 , wherein Z is CH(CO2R4) (CH2).

8. The compound of claim 1 , selected from any of: Nα-Boc-L-Lys(Cbz)-Nip-β-Ala-OBn (CP #1);
Nα-Boc-L-Lys-Nip-β-Ala-OH (CP #2);
Nα-Boc-D-Lys-Nip-β-Ala-OH (CP #3);
H-L-Lys-Nip-β-Ala-OH (CP #4);
N-(Nε-Aminocaproyl)-Nip-β-Ala-OH (CP #5);
Nα-Ac-L-Lys-Nip-Gly-OH (CP #6);
Nα-Ac-L-Lys-Nip-β-Ala-OH (CP #7);
Nα-Boc-L-Arg-Nip-β-Ala-OH (CP #8);
Nα-Boc-L-Lys-Nip-γ-aminobutyric acid (CP #9);
H-D-Lys-Nip-β-Ala-OH (CP #10);
Nα-Boc-D-Lys-Nip-γ-aminobutyric acid (CP #11);
Nα-Boc-D-Lys-Nip-Gly-OH (CP #12);
Nα-Ac-D-Lys-Nip-β-Ala-OH (CP #13);
Nα-Boc-D-Lys-S-(+)-Nip-β-Ala-OH (CP #14);
Nα-Boc-L-Lys(i-Pr)-Nip-β-Ala-OH (CP #15);
Nα-Boc-D-Lys-Rr(-)-Nip-β-Ala-OH (CP #16);
N-[3-(4-Piperidinepropionyl)]-Nip-β-Ala-OH (CP #17);
Nα-Boc-D-Lys-Nip-L-Asp-OMe (CP #18); or
N-(Nε-Aminocaproyl)-3-piperidinemethylaminopropionic acid (CP #19)

AU21191/95A
1994-03-16
1995-03-14
Nipecotic acid derivatives as antithrombic compounds

Ceased

AU703397B2
(en)

Applications Claiming Priority (5)

Application Number
Priority Date
Filing Date
Title

US21377294A

1994-03-16
1994-03-16

US08/213772

1994-03-16

US36489694A

1994-12-27
1994-12-27

US08/364896

1994-12-27

PCT/US1995/003145

WO1995025091A2
(en)

1994-03-16
1995-03-14
Nipecotic acid derivatives as antithrombic compounds

Publications (2)

Publication Number
Publication Date

AU2119195A
true

AU2119195A
(en)

1995-10-03

AU703397B2

AU703397B2
(en)

1999-03-25

Family
ID=26908383
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU21191/95A
Ceased

AU703397B2
(en)

1994-03-16
1995-03-14
Nipecotic acid derivatives as antithrombic compounds

Country Status (20)

Country
Link

US
(1)

US5770575A
(en)

EP
(1)

EP0746545B1
(en)

JP
(1)

JPH09510453A
(en)

KR
(1)

KR100328287B1
(en)

CN
(1)

CN1083834C
(en)

AT
(1)

ATE180470T1
(en)

AU
(1)

AU703397B2
(en)

CA
(1)

CA2163027A1
(en)

DE
(1)

DE69509875T2
(en)

DK
(1)

DK0746545T3
(en)

ES
(1)

ES2131313T3
(en)

FI
(1)

FI113763B
(en)

GR
(1)

GR3030566T3
(en)

HU
(1)

HUT74871A
(en)

MX
(1)

MX9504800A
(en)

NO
(1)

NO304885B1
(en)

NZ
(1)

NZ283209A
(en)

RU
(1)

RU2135470C1
(en)

TW
(1)

TW318179B
(en)

WO
(1)

WO1995025091A2
(en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

RU2161155C2
(en)

1993-09-22
2000-12-27
Фудзисава Фармасьютикал Ко., Лтд
Derivatives of n-(3-piperidinylcarbonyl)-beta-alanine as antagonists of platelet activation factor, method of synthesis, pharmaceutical composition and method of treatment

WO1996029309A1
(en)

1995-03-17
1996-09-26
Fujisawa Pharmaceutical Co., Ltd.
N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS

KR19990087694A
(en)

1996-03-13
1999-12-27
후지야마 아키라

N-[(R) -l- {3- (4-piperidyl) propionyl-3-piperidylcarbonyl] -2 (S) -acetylamino-β-alanine as a fibrinogen receptor antagonist

CN1286684A
(en)

1996-05-01
2001-03-07
奥索·麦克尼尔药品公司
Carboxamide derivs. of pyrrolidine, piperidine and hexahydroazepine for treatment of thrombosis disorders

EP1184374B1
(en)

1996-05-01
2009-01-28
Ortho-McNeil Pharmaceutical, Inc.
Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders

DE19741235A1
(en)

1997-09-18
1999-03-25
Hoechst Marion Roussel De Gmbh

Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them

US6066651A
(en)

1997-10-29
2000-05-23
Ortho-Mcneil Pharmaceutical, Inc.
Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders

US6020347A
(en)

1997-11-18
2000-02-01
Merck & Co., Inc.
4-substituted-4-piperidine carboxamide derivatives

WO1999025685A1
(en)

1997-11-18
1999-05-27
Merck & Co., Inc.
4-substituted-4-piperidine carboxamide derivatives

AU775413B2
(en)

1999-03-22
2004-07-29
Ortho-Mcneil Pharmaceutical, Inc.
Process for preparing (S-(R*,S*)) -beta -(((1-(1-oxo-3- (4-piperidinyl) propyl) -3-piperidinyl) carbonyl) amino) -3- pyridinepropanoic acid and derivatives

AUPQ570100A0
(en)

2000-02-17
2000-03-09
Fujisawa Pharmaceutical Co., Ltd.
Beta-alanine derivatives and their use as receptor antagonists

WO2005079863A1
(en)

2004-02-25
2005-09-01
Astellas Pharma Inc.
Contrast medium for thrombus formation

EP3184149A1
(en)

2015-12-23
2017-06-28
Julius-Maximilians-Universität Würzburg
Soluble glycoprotein v for treating thrombotic diseases

CN109734655B
(en)

2019-03-11
2020-06-02
都创(上海)医药科技有限公司
Synthesis process of homodimer of FKBP ligand

Family Cites Families (8)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4857508A
(en)

1987-12-03
1989-08-15
Monsanto Company
Novel platelet-aggregation inhibitor peptide derivatives

US5318899A
(en)

1989-06-16
1994-06-07
Cor Therapeutics, Inc.
Platelet aggregation inhibitors

TW201303B
(en)

1990-07-05
1993-03-01
Hoffmann La Roche

MX9100517A
(en)

1990-08-06
1992-04-01
Smith Kline French Lab

COMPOUNDS

DE69222433D1
(en)

1991-11-22
1997-10-30
Yeda Res & Dev

NON-PEPTIDIC SURROGATES OF THE ARG-GLY-ASP SEQUENCE AND RELATED PHARMACEUTICAL COMPOSITIONS

US5219867A
(en)

1991-12-16
1993-06-15
Research Corporation Technologies, Inc.
Platelet aggregation inhibitory agents

ATE184882T1
(en)

1992-12-11
1999-10-15
Univ Florida

MATERIALS AND METHODS FOR PEST CONTROL

US5559209A
(en)

1993-02-18
1996-09-24
The General Hospital Corporation
Regulator regions of G proteins

1995

1995-03-06
US
US08/395,533
patent/US5770575A/en
not_active
Expired – Lifetime

1995-03-14
CN
CN95190367A
patent/CN1083834C/en
not_active
Expired – Fee Related

1995-03-14
DE
DE69509875T
patent/DE69509875T2/en
not_active
Expired – Fee Related

1995-03-14
MX
MX9504800A
patent/MX9504800A/en
not_active
IP Right Cessation

1995-03-14
ES
ES95914023T
patent/ES2131313T3/en
not_active
Expired – Lifetime

1995-03-14
JP
JP7524128A
patent/JPH09510453A/en
active
Pending

1995-03-14
HU
HU9503270A
patent/HUT74871A/en
unknown

1995-03-14
EP
EP95914023A
patent/EP0746545B1/en
not_active
Expired – Lifetime

1995-03-14
DK
DK95914023T
patent/DK0746545T3/en
active

1995-03-14
CA
CA002163027A
patent/CA2163027A1/en
not_active
Abandoned

1995-03-14
AT
AT95914023T
patent/ATE180470T1/en
not_active
IP Right Cessation

1995-03-14
KR
KR1019950705100A
patent/KR100328287B1/en
not_active
IP Right Cessation

1995-03-14
AU
AU21191/95A
patent/AU703397B2/en
not_active
Ceased

1995-03-14
RU
RU95122287A
patent/RU2135470C1/en
not_active
IP Right Cessation

1995-03-14
WO
PCT/US1995/003145
patent/WO1995025091A2/en
active
IP Right Grant

1995-03-14
NZ
NZ283209A
patent/NZ283209A/en
unknown

1995-11-15
FI
FI955498A
patent/FI113763B/en
active

1995-11-15
NO
NO954609A
patent/NO304885B1/en
unknown

1995-12-18
TW
TW084113492A
patent/TW318179B/en
active

1999

1999-06-17
GR
GR990401649T
patent/GR3030566T3/en
unknown

Also Published As

Publication number
Publication date

DE69509875T2
(en)

1999-12-09

HUT74871A
(en)

1997-02-28

ATE180470T1
(en)

1999-06-15

WO1995025091A2
(en)

1995-09-21

AU703397B2
(en)

1999-03-25

CA2163027A1
(en)

1995-09-21

ES2131313T3
(en)

1999-07-16

US5770575A
(en)

1998-06-23

NZ283209A
(en)

1998-04-27

TW318179B
(en)

1997-10-21

KR100328287B1
(en)

2002-10-11

HU9503270D0
(en)

1996-05-28

CN1083834C
(en)

2002-05-01

JPH09510453A
(en)

1997-10-21

DK0746545T3
(en)

1999-11-08

EP0746545A1
(en)

1996-12-11

FI955498A
(en)

1996-01-15

FI955498A0
(en)

1995-11-15

GR3030566T3
(en)

1999-10-29

RU2135470C1
(en)

1999-08-27

MX9504800A
(en)

1997-05-31

NO954609D0
(en)

1995-11-15

NO954609L
(en)

1996-01-05

FI113763B
(en)

2004-06-15

WO1995025091A3
(en)

1995-10-12

DE69509875D1
(en)

1999-07-01

EP0746545B1
(en)

1999-05-26

NO304885B1
(en)

1999-03-01

CN1128022A
(en)

1996-07-31

Información de contacto